DekaBank Deutsche Girozentrale Purchases 23,768 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

DekaBank Deutsche Girozentrale boosted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 26.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 115,308 shares of the specialty pharmaceutical company’s stock after purchasing an additional 23,768 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.18% of Jazz Pharmaceuticals worth $13,938,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Teachers Retirement System of The State of Kentucky grew its holdings in Jazz Pharmaceuticals by 45.3% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 161,388 shares of the specialty pharmaceutical company’s stock worth $19,434,000 after buying an additional 50,300 shares in the last quarter. Virtu Financial LLC grew its stake in shares of Jazz Pharmaceuticals by 31.8% in the 1st quarter. Virtu Financial LLC now owns 11,696 shares of the specialty pharmaceutical company’s stock worth $1,408,000 after acquiring an additional 2,819 shares in the last quarter. Plato Investment Management Ltd purchased a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at about $228,000. Tidal Investments LLC lifted its position in shares of Jazz Pharmaceuticals by 179.4% during the first quarter. Tidal Investments LLC now owns 16,655 shares of the specialty pharmaceutical company’s stock valued at $2,006,000 after purchasing an additional 10,693 shares in the last quarter. Finally, California State Teachers Retirement System lifted its position in shares of Jazz Pharmaceuticals by 3.2% during the first quarter. California State Teachers Retirement System now owns 102,353 shares of the specialty pharmaceutical company’s stock valued at $12,325,000 after purchasing an additional 3,172 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ traded down $1.12 during midday trading on Friday, hitting $113.26. The company’s stock had a trading volume of 716,259 shares, compared to its average volume of 655,591. The firm has a market capitalization of $7.14 billion, a price-to-earnings ratio of 23.35, a P/E/G ratio of 1.76 and a beta of 0.58. The company has a current ratio of 2.37, a quick ratio of 1.90 and a debt-to-equity ratio of 1.36. The stock has a fifty day moving average price of $107.82 and a 200 day moving average price of $114.11. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The company had revenue of $901.98 million for the quarter, compared to analysts’ expectations of $938.99 million. On average, research analysts forecast that Jazz Pharmaceuticals plc will post 15.31 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday. The Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They set a “buy” rating and a $169.00 price target for the company. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Needham & Company LLC reduced their price objective on Jazz Pharmaceuticals from $208.00 to $205.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Barclays lowered their target price on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Friday, May 3rd. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $175.20.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.